Warning Letter to Melvin Williams 2006

February 12, 2008

Department of Health and Human Services' logo Department of Health and Human Services

Public Health Service
Food and Drug Administration
Southwest Region


Kansas City District
11630 W 80th St
Lenexa, KS 66214-3340
Telephone: 913-752-2100

February 2, 2006

Melvin Williams
9408 Bales
Kansas City, MO 64132

Ref. No. KAN 2006-06

Dear Mr Williams:

The Food and Drug Administration (FDA) has reviewed your website at the Internet address www.cuttingedgehealth101.com and has concluded that claims in the labeling for your product Natural Cellular Defense cause the product to be a drug as defined in section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 USC 321(g)(1)(B)]. You can find the Act and FDA’s regulations through links on FDA�s Internet homepage: www.fda.gov.

Under the Act, articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man are drugs [Section 201(g)(1)(B) of the Act, 21 USC 321(g)(1)(B)]. Your website claims that your product is useful in the prevention and treatment of avian flu and other forms of influenza.

The Internet labeling of your products bears the following implied claims:

  • “Are you concerned about the Bird Flu?”
  • “Who else wants a natural supplement that can ‘interrupt’ a virus life cycle?”
  • “With the new super viruses we are told to be on the lookout for, doesn�t it make sense to arm yourself with a Patented natural virus shield?”

These claims cause your product to be a drug, as defined in section 201(g)(1)(B) of the Act [21 USC 321(g)(1)(B)]. Because your product is not generally recognized as safe and effective when used as labeled, it is also a new drug as defined in section 201(p) of the Act [21 USC 321(p)]. Under section 505 of the Act [21 USC 355 (a)], a new drug may not be legally marketed in the United States without an approved New Drug Application (NDA). This drug is also misbranded within the meaning of section 502(a) of the Act [21 USC 352(a)] because their labeling is false and misleading in that it suggests that this drug is effective for the prevention and treatment of avian flu and other forms of influenza when, in fact, these claims are not supported by competent and reliable scientific evidence.

This letter is not intended to be an all-inclusive review of your website and products your firm markets. It is your responsibility to ensure that all products marketed by your firm comply with the Act and its implementing regulations.

You must immediately correct these violations. If you do not immediately correct them, you may be subject to enforcement action without notice. The Act provides for seizure of illegal products and for injunctions against the manufacturers and distributors of illegal products [21 USC 332 and 334]. Individuals and businesses that violate the Act may also be subject to criminal prosecution.

Please advise this office, in writing and within fifteen (15) working days of the receipt of this letter, as to the specific steps you haven taken to correct the violations noted above and to ensure that similar violations do not occur. If corrective actions cannot be completed within fifteen working days, state the reason for the delay and the time within which the corrections will be completed.

Your reply should be addressed to Compliance Officer Joseph G. Kramer at the above address.

John W. Thorsky
District Director

This page was posted on February 12, 2008.